Marc Duey insider trades: Aprea Therapeutics (APRE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Marc reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | APRE | ↑ Buy | 21,459 | $1.17 | $25K | Direct | Dec 11, 2025 (1d) |
| Oct 18, 2024 | APRE | ↓ Sell | 6,462 | $4.58 | $30K | Direct | Oct 25, 2024 (7d) |
| Oct 16, 2024 | APRE | ↑ Buy | 30,000 | $4.39 | $132K | Direct | Oct 17, 2024 (1d) |
| Oct 14, 2024 | APRE | ↑ Buy | 190 | $2.58 | $490 | Direct | Oct 16, 2024 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other APRE insiders
Open-market trades in the last 12 months
About Marc Duey's insider trades
Marc Duey is a director at Aprea Therapeutics (APRE). Since Oct 14, 2024, Marc has reported 3 open-market purchases worth $157K and 1 sale worth $30K on SEC Form 4. In the last 12 months: 1 buy ($25K).
Their filings also include grants and awards (5 filings), other transactions (1 filing), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every APRE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.